Dr Nigel Sansom,PhD,MBA

Originally trained in molecular pathology, Nigel has over twenty years of pharmaceutical, biotechnology and healthcare experience, having held senior level roles with Astra Zeneca, Novartis, Intergen Inc., and the NHS.

As a member of the core team that originally set up the NHS National Innovation Centre, Nigel has developed an international reputation for his involvement in innovation and the development of medical technology and diagnostics.


Giles tully

Giles Tully is an entrepreneur, angel investor and philanthropist with a broad range of business interests; from industrial agriculture to viral marketing, music and film, MedTech, BioTech, New Media, property, advertising and crowdfunding. Having spent a decade in Beijing he is fluent in mandarin Chinese and is used to working internationally with both major brands and startups.

Inspired by Pinpoint Giles joined in 2016 to help drive the transition from academic research into the world of commerce without diluting the mission to create a pan-cancer blood test.



Chief Scientific Officer

Dr richard savage

Dr Rich Savage is an expert in statistical machine learning and its application to important problems in healthcare.  He has a particular interest in developing statistical modelling approaches for complex high-dimensional biomedical data types and the translation of those methods into clinical practice. 

Beginning his career as an astrophysicist Rich created data analysis pipelines for space telescopes, measured the age of the universe using the light from the Big Bang and helped build a telescope on the side of a volcano.

He has published over 50 papers in peer-reviewed journals, and is currently an Associate Professor in the University of Warwick's Department of Statistics.                                    

Chair of Scientific Advisory Board

Professor ala Szczepura

Ala Szczepura is Professor of Health Technology Assessment at Coventry University. She has over thirty years’ experience of interdisciplinary research in health. Her research interests focus on the evaluation of new and emerging technologies and models of care. She combines expertise in policy research and health economics with an academic interest in the organisation and management of health care, including evaluation of effectiveness, costs and broader social and ethical implications of new technologies.

She was seconded to the Department of Health to help establish the national HTA Research Programme and sat on the Programme Commissioning Board. Professor Szczepura is originally a scientist, having run a number of scientific research programmes in industry and academia.     


PinPoint Cancer is supported by an experienced Scientific Advisory Board:

  • Dr Michael Messenger, Deputy Director and Scientific Manager - NIHR Diagnostic Evidence Co-operative Leeds
  • Professor Orla Sheils, Trinity Translational Medicine Institute, Trinity College Dublin
  • Professor Tony Whetton, Vice Dean, Faculty of Medical and Human Sciences, University of Manchester
  • Professor Finbarr Cotter, Barts Health NHS Trust, Barts and the London School of Medicine
  • Dr Ann Dalton, Director of Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust
  • Dr Sophie Whyte, School of Health and Related Research, University of Sheffield
  • Dr Dawn Teare, Reader in Epidemiology and Biostatistics, University of Sheffield
  • Professor Angie Cox, Sheffield Cancer Research, University of Sheffield
  • Dr Caroline Chapman, Programme Manager, NHS Bowel Cancer Screening Programme, Eastern Hub.
  • Dr James Covington, Associate Professor, Warwick, Biomedical Sensors Laboratory.


Uttley L, Whiteman BL, Woods HB, Harnan S, Philips ST, Cree IA; Early Cancer Detection Consortium. Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review.  EBioMedicine. 2016 Jul 6.
pii: S2352-3964(16)30309-7. doi: 10.1016/j.ebiom.2016.07.004.  

Cree IA.  Liquid Biopsy for Cancer Patients: Principles and Practice.  Pathogenesis. 2015; 2(1): 1 – 4, DOI: